Literature DB >> 33529148

Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts.

Mickael Orgeur1, Wafa Frigui1, Alexandre Pawlik1, Simon Clark2, Ann Williams2, Louis S Ates3,1, Laurence Ma4, Christiane Bouchier4, Julian Parkhill5,6, Priscille Brodin7, Roland Brosch1.   

Abstract

Mycobacterium microti is an animal-adapted member of the Mycobacterium tuberculosis complex (MTBC), which was originally isolated from voles, but has more recently also been isolated from other selected mammalian hosts, including occasionally from humans. Here, we have generated and analysed the complete genome sequences of five representative vole and clinical M. microti isolates using PacBio- and Illumina-based technologies, and have tested their virulence and vaccine potential in SCID (severe combined immune deficient) mouse and/or guinea pig infection models. We show that the clinical isolates studied here cluster separately in the phylogenetic tree from vole isolates and other clades from publicly available M. microti genome sequences. These data also confirm that the vole and clinical M. microti isolates were all lacking the specific RD1mic region, which in other tubercle bacilli encodes the ESX-1 type VII secretion system. Biochemical analysis further revealed marked phenotypic differences between isolates in type VII-mediated secretion of selected PE and PPE proteins, which in part were attributed to specific genetic polymorphisms. Infection experiments in the highly susceptible SCID mouse model showed that the clinical isolates were significantly more virulent than the tested vole isolates, but still much less virulent than the M. tuberculosis H37Rv control strain. The strong attenuation of the ATCC 35872 vole isolate in immunocompromised mice, even compared to the attenuated BCG (bacillus Calmette-Guérin) vaccine, and its historic use in human vaccine trials encouraged us to test this strain's vaccine potential in a guinea pig model, where it demonstrated similar protective efficacy as a BCG control, making it a strong candidate for vaccination of immunocompromised individuals in whom BCG vaccination is contra-indicated. Overall, we provide new insights into the genomic and phenotypic variabilities and particularities of members of an understudied clade of the MTBC, which all share a recent common ancestor that is characterized by the deletion of the RD1mic region.

Entities:  

Keywords:  ESX-1; Mycobacterium microti; mouse and guinea pig models; protective efficacy; virulence evaluation; whole-genome sequencing

Year:  2021        PMID: 33529148     DOI: 10.1099/mgen.0.000505

Source DB:  PubMed          Journal:  Microb Genom        ISSN: 2057-5858


  8 in total

1.  ESX-1-Independent Horizontal Gene Transfer by Mycobacterium tuberculosis Complex Strains.

Authors:  Jan Madacki; Mickael Orgeur; Guillem Mas Fiol; Wafa Frigui; Laurence Ma; Roland Brosch
Journal:  mBio       Date:  2021-05-18       Impact factor: 7.867

2.  Genotypic and phenotypic diversity of Mycobacterium tuberculosis complex genotypes prevalent in West Africa.

Authors:  Stephen Osei-Wusu; Isaac Darko Otchere; Portia Morgan; Abdul Basit Musah; Ishaque Mintah Siam; Diana Asandem; Theophilus Afum; Prince Asare; Adwoa Asante-Poku; Kwadwo Asamoah Kusi; Sebastien Gagneux; Dorothy Yeboah-Manu
Journal:  PLoS One       Date:  2021-08-26       Impact factor: 3.240

3.  Multiple genetic paths including massive gene amplification allow Mycobacterium tuberculosis to overcome loss of ESX-3 secretion system substrates.

Authors:  Lin Wang; Emmanuel Asare; Amol C Shetty; Freddy Sanchez-Tumbaco; Megan R Edwards; Rajagopalan Saranathan; Brian Weinrick; Jiayong Xu; Bing Chen; Angèle Bénard; Gordon Dougan; Daisy W Leung; Gaya K Amarasinghe; John Chan; Christopher F Basler; William R Jacobs; JoAnn M Tufariello
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-22       Impact factor: 12.779

4.  The impact of frequently neglected model violations on bacterial recombination rate estimation: a case study in Mycobacterium canettii and Mycobacterium tuberculosis.

Authors:  Susanna Sabin; Ana Y Morales-Arce; Susanne P Pfeifer; Jeffrey D Jensen
Journal:  G3 (Bethesda)       Date:  2022-05-06       Impact factor: 3.542

5.  Ocular mycobacterial lesions in cats.

Authors:  Jordan L Mitchell; Laura MacDougall; Melanie J Dobromylskyj; Ken Smith; Renata Stavinohova; Danièlle A Gunn-Moore; Jayne C Hope; Emma Scurrell
Journal:  Vet Pathol       Date:  2022-05-19       Impact factor: 3.157

Review 6.  Mycobacterium microti Infections in Free-Ranging Red Deer (Cervus elaphus).

Authors:  Giovanni Ghielmetti; Anne M Kupca; Matthias Hanczaruk; Ute Friedel; Hubert Weinberger; Sandra Revilla-Fernández; Erwin Hofer; Julia M Riehm; Roger Stephan; Walter Glawischnig
Journal:  Emerg Infect Dis       Date:  2021-08       Impact factor: 6.883

7.  A Comprehensive Map of Mycobacterium tuberculosis Complex Regions of Difference.

Authors:  D Bespiatykh; J Bespyatykh; I Mokrousov; E Shitikov
Journal:  mSphere       Date:  2021-07-21       Impact factor: 4.389

8.  PPE38-Secretion-Dependent Proteins of M. tuberculosis Alter NF-kB Signalling and Inflammatory Responses in Macrophages.

Authors:  James Gallant; Tiaan Heunis; Caroline Beltran; Karin Schildermans; Sven Bruijns; Inge Mertens; Wilbert Bitter; Samantha L Sampson
Journal:  Front Immunol       Date:  2021-07-02       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.